|
|
|
|
| LEADER |
02671nam a2200313 u 4500 |
| 001 |
EB000942657 |
| 003 |
EBX01000000000000000736247 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150223 r ||| eng |
| 100 |
1 |
|
|a Helfand, Mark
|
| 245 |
0 |
0 |
|a Benign prostatic hyperplasia (BPH) management in primary care
|h Elektronische Ressource
|b screening and therapy : final report February 2007
|c Mark Helfand, Tara Muzyk, Mark Garzotto
|
| 260 |
|
|
|a [Washington, D.C.]
|b Dept. of Veterans Affairs, Health Services Research & Development Service
|c 2007, [2007]
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a 5-alpha Reductase Inhibitors / therapeutic use
|
| 653 |
|
|
|a Adrenergic alpha-1 Receptor Antagonists / therapeutic use
|
| 653 |
|
|
|a Drug Therapy, Combination
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Prostatic Hyperplasia / drug therapy
|
| 700 |
1 |
|
|a Muzyk, Tara
|
| 700 |
1 |
|
|a Garzotto, Mark
|
| 710 |
2 |
|
|a United States
|b Department of Veterans Affairs
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Evidence synthesis pilot program
|
| 500 |
|
|
|a Title from PDF t.p. (viewed Jan. 10, 2011). - "Comparative effectiveness review.". - Mode of access: Internet
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK49208
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Benign prostatic hyperplasia (BPH) causes urinary hesitancy and intermittency, weak urine stream, nocturia, frequency, urgency, and the sensation of incomplete bladder emptying. These symptoms, collectively called "lower urinary tract symptoms," or LUTS, can significantly reduce quality of life. Men with no symptoms or mild symptoms (AUA Symptom Index [SI] score of <7 points), and those who tolerate moderate symptoms well, may be managed without pharmacotherapy ("watchful waiting"). For those who have moderate or severe symptoms, medical treatments include alpha-1-selective adrenergic receptor (a-1-AR) antagonists, 5-alpha-reductase inhibitors (5-aRIs), or a combination therapy with one drug from each of these classes. This report addresses the following questions about treatment for BPH: For patients with BPH, what are the comparative benefits, harms, and efficacy of combination therapy with a 5-alpha-reductase inhibitor plus an alpha blocker versus either treatment alone? What are the comparative efficacy and harms of alpha-1-adrenergic antagonists? Are there subgroups of patients based on demographics (age, racial groups), other medications, or co-morbidities for which one treatment is more effective or associated with fewer adverse events?
|